Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that ...
The test could potentially deliver noninvasive results in less than one minute through analysis of exhaled volatile organic compounds.
Evvy, the precision women's health company, today announced the launch of the Evvy UTI+ Test, a comprehensive at-home urine test that uses PCR technology to detect 12 key uropathogens and 7 antibiotic ...
NAAT tests, including PCR tests, are more likely to detect the virus, and are considered the “gold standard” for COVID-19 ...
Evvy’s new UTI+ Test and microbiome tools deliver faster, clearer insights into BV and UTI care, reshaping women’s health ...
African Swine Fever Polymerase Chain Reaction (ASF-PCR) test kits being kept in the cold storage of the Bacolod City Local ...
The DNA Diagnostics Market is set to surge from USD 13.07 billion in 2024 to USD 21.69 billion by 2030, growing at a CAGR of ...
The new PCR test aids in the diagnosis of infectious causes of vaginitis through the detection of bacteria associated with bacterial vaginosis and yeast associated with candida vaginitis. The test ...
The new HER2DX central nervous system (CNS) progression score predicts risk of brain progression in advanced HER2+ breast cancer, addressing a major unmet need in identifying patients at the highest ...
Attendees interested in learning more about CoSara products, including the TB and HPV tests on the Company's upcoming Co-Dx PCR platform, are encouraged to stop by at VIROCON 2025. CoSara will be ...
The test, which will use Iso-PAS technology, will be developed by Nipro of Japan in collaboration with other companies, institutes, and nonprofit organizations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback